<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3080">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437111</url>
  </required_header>
  <id_info>
    <org_study_id>0217A-329</org_study_id>
    <nct_id>NCT01437111</nct_id>
  </id_info>
  <brief_title>Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)</brief_title>
  <official_title>A Phase III (Phase IV Program) Open-Label, Multicenter Clinical Trial in Thailand to Study the Effect of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) for 6 Months on 25-Hydroxyvitamin D Levels in the Treatment of Osteoporosis in Postmenopausal Women and Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effect of 26 weeks of once-weekly treatment with
      MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus
      70/5600) on serum levels of 25-hydroxyvitamin D [25(OH)D].
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Serum 25-hydroxyvitamin D &gt;=50 ng/mL at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum samples to measure serum 25-hydroxyvitamin D [25(OH)D] will be collected at specific visits during the treatment phase of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline of Bone Resorption Marker of Serum Beta-CrossLaps at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum samples for Beta-CrossLaps (Î²-CTx) will be collected at specific visits during the treatment phase of the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Fosamax Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium supplement (elemental calcium and/or calcium carbonate) without vitamin D will also be supplied to participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet</intervention_name>
    <description>One combination tablet orally once a week</description>
    <arm_group_label>Fosamax Plus</arm_group_label>
    <other_name>Fosamax Plus 70/5600</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man aged 50 or older, or a woman who is postmenopausal on day of signing informed
             consent or has been menopausal for at least one year

          -  Meets bone mineral density (BMD) criteria

          -  Agree to discontinue any osteoporosis drug treatment for duration of study

        Exclusion Criteria:

          -  Any contraindication to alendronate and vitamin D

          -  Not ambulatory

          -  Has received treatment with any anabolic steroid agent within the past 12 months,
             systemic glucocorticoids, for more than 2 weeks in the past 6 months, current use of
             immunosuppressants, fluoride treatment at a dose greater than 1 mg/day for more than
             2 weeks within the past 3 months, treated with parathyroid hormone (PTH) for more
             than 2 weeks within the past 3 months, current use of chemotherapy or heparin, use of
             growth hormone for more than 2 weeks within the past 6 months, use of active hormonal
             vitamin D analogs in the past 2 months, current use of vitamin A &gt;10,000 IU daily,
             current use of, lithium, or anti-convulsants including barbiturates, hydantoins, and
             carbamazepine, current use of calcium supplement in amount excess of 1500 mg daily,
             and/or current use of Vitamin D supplement

          -  History of malignancy &lt;5 years, except adequately treated basal cell or squamous cell
             skin cancer and in situ cervical cancer

          -  One or more of the following concomitant conditions: Upper gastrointestinal (GI)
             disorders not adequately controlled; myocardial infarction, unstable angina, stroke
             and revascularization condition within 3 months; malabsorption syndrome; primary or
             secondary hyperparathyroidism not adequately treated; thyroid disease not adequately
             controlled; severe renal insufficiency; uncontrolled genitourinary, cardiovascular,
             hepatic, renal, endocrine, hematologic, neurological, psychiatric, or pulmonary
             diseases; uncontrolled hypertension; new onset diabetes (within 3 months), poorly
             controlled hyperglycemia, or hypoglycemia for any cause; evidence for metabolic bone
             disease other than osteoporosis; abnormal indices of calcium metabolism; and/or
             active renal stone disease

          -  User of illicit recreational drugs or has had a recent history (within the last year)
             of drug or alcohol abuse or dependence

          -  Heavy consumer of alcohol or alcohol containing products.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 27, 2015</lastchanged_date>
  <firstreceived_date>September 19, 2011</firstreceived_date>
  <firstreceived_results_date>December 3, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Postmenopausal</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fosamax Plus: All Participants</title>
          <description>All participants who were enrolled in the study to receive one oral combination tablet of Fosamax Plus weekly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Participants</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not reported</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Analysis was performed on the All Patients as Treated (APaT) population, which included all participants who received treatment. Of 200 participants enrolled in the study, baseline data were not provided for two participants who did not receive treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Fosamax Plus: All Treated Participants</title>
          <description>All participants who received at least one oral dose combination tablet of Fosamax Plus.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="198"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age data were not reported for 2 participants.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="68.81" spread="8.39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender data were not reported for 2 participants.</description>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="193"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serum 25-hydroxyvitamin D &gt;=50 ng/mL at Week 26</title>
        <description>Serum samples to measure serum 25-hydroxyvitamin D [25(OH)D] will be collected at specific visits during the treatment phase of the study.</description>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set (FAS) consisted of participants who received &gt;=1 dose of study drug; had &gt;=1 post-baseline observation for the analysis endpoint; and had baseline data. For analysis, participants in the FAS were categorized into 3 subgroups by osteoporosis therapy received at baseline: Recent/Current, Other therapy, and Treatment NaÃ¯ve</population>
        <group_list>
          <group group_id="O1">
            <title>Fosamax Plus: Recent/Current Osteoporosis Therapy at Baseline</title>
            <description>Participants receiving recent/current osteoporosis therapy at baseline (including bisphosphonate, strontium, estrogen, or SERM were administered open-label alendronate sodium 70 mg+Vitamin D3 5600 IU combination tablet (Fosamax Plus D) orally once a week for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fosamax Plus: Other Osteoporosis Therapy at Baseline</title>
            <description>Participants receiving other osteoporosis drugs at baseline (besides bisphosphonate, strontium, estrogen, or SERM) were administered open-label alendronate sodium 70 mg+Vitamin D3 5600 IU combination tablet (Fosamax Plus D) orally once a week for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fosamax Plus: Treatment Naive at Baseline</title>
            <description>Participants that were treatment-naÃ¯ve or not recently treated at baseline were administered open-label alendronate sodium 70 mg+Vitamin D3 5600 IU combination tablet (Fosamax Plus D) orally once a week for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Fosamax Plus: All Treated Participants</title>
            <description>All participants who received at least one oral dose combination tablet of Fosamax Plus.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="64"/>
                  <measurement group_id="O3" value="94"/>
                  <measurement group_id="O4" value="186"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Serum 25-hydroxyvitamin D &gt;=50 ng/mL at Week 26</title>
            <description>Serum samples to measure serum 25-hydroxyvitamin D [25(OH)D] will be collected at specific visits during the treatment phase of the study.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline of Bone Resorption Marker of Serum Beta-CrossLaps at Week 26</title>
        <description>Serum samples for Beta-CrossLaps (Î²-CTx) will be collected at specific visits during the treatment phase of the study.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population consisted of FAS but excluded participants who had important deviations from protocol or did not complete study on study drug. For analysis, participants in Per Protocol Population were categorized into 3 subgroups by osteoporosis therapy received at baseline: Recent/Current, Other therapy, and Treatment NaÃ¯ve.</population>
        <group_list>
          <group group_id="O1">
            <title>Fosamax Plus: Recent/Current Osteoporosis Therapy at Baseline</title>
            <description>Participants receiving recent/current osteoporosis therapy at baseline (including bisphosphonate, strontium, estrogen, or SERM were administered open-label alendronate sodium 70 mg+Vitamin D3 5600 IU combination tablet (Fosamax Plus D) orally once a week for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fosamax Plus: Other Osteoporosis Therapy at Baseline</title>
            <description>Participants receiving other osteoporosis drugs at baseline (besides bisphosphonate, strontium, estrogen, or SERM) were administered open-label alendronate sodium 70 mg+Vitamin D3 5600 IU combination tablet (Fosamax Plus D) orally once a week for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fosamax Plus: Treatment Naive at Baseline</title>
            <description>Participants that were treatment-naÃ¯ve or not recently treated at baseline were administered open-label alendronate sodium 70 mg+Vitamin D3 5600 IU combination tablet (Fosamax Plus D) orally once a week for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Fosamax Plus: All Treated Participants</title>
            <description>All participants who received at least one oral dose combination tablet of Fosamax Plus.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="62"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="182"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Percent Change From Baseline of Bone Resorption Marker of Serum Beta-CrossLaps at Week 26</title>
            <description>Serum samples for Beta-CrossLaps (Î²-CTx) will be collected at specific visits during the treatment phase of the study.</description>
            <units>Percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-12.65" spread="56.94"/>
                  <measurement group_id="O2" value="-49.82" spread="35.08"/>
                  <measurement group_id="O3" value="-76.81" spread="20.33"/>
                  <measurement group_id="O4" value="-57.74" spread="40.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 26</time_frame>
      <desc>Of 200 participants enrolled in the study, two participants did not receive treatment and were not evaluated for safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fosamax Plus: All Treated Participants</title>
          <description>All participants who received at least one oral dose combination tablet of Fosamax Plus.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tongue neoplasm, malignant stage, unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators agreed to allow the Sponsor to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Investigators have also agreed that any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
